Liminatus Pharma, Inc. 2025 Annual Report: Key Highlights and Investor Insights

Ticker: LIMN
Exchange: The Nasdaq Stock Market LLC
Fiscal Year End: December 31, 2025
Common Shares Outstanding (as of March 27, 2026): 44,877,633
Public Float (as of June 30, 2025): \$221 million

Key Points from the 2025 Annual Report

• Significant Growth in Shares Outstanding: The company reported a substantial increase in its outstanding common stock from 26,014,633 shares as of June 30, 2025, to 44,877,633 shares as of March 27, 2026. This suggests significant corporate activity, such as capital raises, acquisitions, or conversions, which may impact existing shareholder value.
• Strong Public Float: The aggregate market value of non-affiliate shares was approximately \$221 million as of June 30, 2025.
• Positive Earnings Momentum: Liminatus reported earnings per diluted share of \$0.43 for 2025, up from \$0.20 in 2024, with a weighted average of 23,753,561 diluted shares outstanding in 2025, compared to 17,500,000 in 2024. This marks an acceleration in financial performance and could be a catalyst for share price appreciation.
• Active in Capital Markets: The company has registered both common stock (LIMN) and warrants (LIMNW) for trading on Nasdaq, signaling active capital management and potential for further financing or strategic transactions.
• Not a Shell Company/Emerging Growth Company: Liminatus is not classified as a shell company. It is a non-accelerated filer, a smaller reporting company, and an emerging growth company, making it eligible for certain regulatory accommodations but also indicating its growth-stage profile.
• Compliance and Regulatory Reporting: The company affirms it is current with its SEC reporting obligations and has submitted all required interactive data files. There have been no restatements or corrections to previous financial statements, and management has not yet had an auditor attestation report on internal controls, which is typical for an emerging growth company.
• No Documents Incorporated by Reference: The annual report is self-contained, with no external documents incorporated, offering investors a single comprehensive source of information.

Forward-Looking Statements and Risk Disclosures

Management has issued a cautionary note highlighting that the report contains forward-looking statements regarding expectations, strategy, and future events. These statements are subject to a wide range of risks and uncertainties, including:

• Changes in competitive markets and industries
• Changes in laws and regulations affecting the business
• Execution risk regarding business plans and forecasts
• Potential inability to achieve or maintain profitability and revenue growth
• Global economic conditions and uncertainty affecting operations
• Risks related to managing growth effectively and retaining key personnel
• Accuracy of financial performance estimates
• Costs and benefits related to business combinations
• Risks related to marketing, growth strategies, and competition
• Need to raise additional capital on reasonable terms
• Risk of delisting from Nasdaq if listing standards are not maintained

These risks are not exhaustive, and actual results could differ significantly from forward-looking statements.

Strategic Direction and Corporate Objectives

• Building a Leading Immuno-Oncology Company: Liminatus emphasizes a strong culture of innovation, diversity, and commitment to patients. This mission supports a long-term investment thesis focused on high-impact medical advances.
• Intellectual Property Protection: The company is actively maintaining, deepening, and protecting its global IP portfolio, a critical element for biotech value creation and competitive positioning.
• Strategic Partnerships and Alliances: Liminatus is seeking alliances, licensing agreements, and collaborations to support research, development, and commercialization—potentially triggering future milestone payments, royalties, or equity investments.

Important Considerations for Shareholders

• Share Dilution Risk: The significant increase in shares outstanding may dilute existing shareholders but could also signal capital inflows supporting growth and R&D initiatives.
• Profitability and Growth Uncertainty: While EPS has risen, management explicitly notes the risk of not achieving sustained profitability or revenue growth, which could affect valuation.
• Nasdaq Listing Risk: The company acknowledges the risk of being unable to maintain its Nasdaq listing, which could materially impact liquidity and share price.
• No Correction or Restatement Events: There have been no restatements or clawbacks of executive compensation due to financial reporting errors, providing confidence in the integrity of reported results.

Conclusion

Liminatus Pharma, Inc. is demonstrating growth in both its capital base and financial results, reinforcing its ambitions in the immuno-oncology sector. However, the rapid increase in outstanding shares, ongoing need for capital, and a broad set of strategic and operational risks mean that investors should closely monitor future developments, especially any corporate actions, partnerships, or regulatory changes that could materially influence share value. The company remains well-positioned in a competitive and innovative field but faces the inherent uncertainties typical of emerging biotech companies.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Forward-looking statements are subject to risks and uncertainties. Investors should consult the full 10-K filing and perform their own due diligence before making investment decisions.

View Liminatus Pharma, Inc. Historical chart here